Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference
03/16/2021 - 11:01 AM
MARINA DEL REY, Calif. , March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference taking place virtually March 16-18, 2021 .
Management is scheduled to present at 3:10pm ET on Wednesday , March 17.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Media Contacts:
At Armata: Steve Martin ir@armatapharma.com
Investor Relations: Joyce Allaire jallaire@lifesciadvisors.com
http://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301248516.html
SOURCE Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals Inc
ARMP Rankings
#3830 Ranked by Stock Gains
ARMP Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Biotechnology, Health Technology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Marina Del Rey
About ARMP
c3 jian is a well-capitalized, private, los angeles based biotechnology company advancing novel compounds that target unmet medical/dental needs related primarily to oral healthcare. the company's lead compound is a unique peptide drug against dental caries (i.e. tooth decay). the company’s lead compound started fda-regulated phase ii human clinical trials in early 2014. c3 jian's platform technology has also yielded peptides that can affect calcification processes, including not only tooth sensitivity but possibly hair and nail growth as well. the company has recently moved its operations to a new facility in marina del rey. the company was founded based on technology created in the laboratory of dr. wenyuan shi, chair of the department of oral biology at the university of california, los angeles school of dentistry. for more information about the company and to explore career opportunities at c3 jian please visit our webpage at www.c3-jian.com
